Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

17.63
+0.15500.89%
Volume:265.36K
Turnover:4.70M
Market Cap:5.62B
PE:36.66
High:17.99
Open:17.57
Low:17.49
Close:17.47
52wk High:19.26
52wk Low:9.32
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.62
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:170.25
PE(LYR):80.11

Loading ...

Amneal Pharmaceuticals to Report Second-quarter 2026 Results, Host Webcast

Reuters
·
Jul 10

Amneal, Adalvo Win FDA Review Acceptance for Generic Tirzepatide Autoinjector Andas

Reuters
·
Jul 09

Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Simply Wall St.
·
Jul 08

Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?

Simply Wall St.
·
Jul 03

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

US FDA - Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin, Regeneron Join FDA Precheck Pilot

THOMSON REUTERS
·
Jun 30

Lilly, Regeneron Selected for US Program to Review New Manufacturing Plants Faster

Reuters
·
Jun 30

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval

MT Newswires Live
·
Jun 29

Zambon and Amneal Announce Positive Chmp Opinion for Hopledo® (ipx203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

THOMSON REUTERS
·
Jun 29

Amneal Partner Zambon Wins Positive EU CHMP Opinion for Parkinson’s Drug Hopledo

Reuters
·
Jun 29

FDA Seeks Updated Labeling for Testosterone Therapies

MT Newswires Live
·
Jun 19

Amneal (AMRX) Stock Valuation Check After Strong Multi Period Gains And Conflicting Fair Value Models

Simply Wall St.
·
Jun 14

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data

Simply Wall St.
·
Jun 06

BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia

Reuters
·
Jun 05

Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results

MT Newswires Live
·
Jun 05

BUZZ-Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study

Reuters
·
Jun 05

Amneal says interim Phase 4 ELEVATE-PD data show Crexont adds about 3 hours daily “Good On” time in Parkinson’s patients

Reuters
·
Jun 05

Amneal Pharma - Phase 4 Data Show Consistent Benefits of Crexont Across All Prior Treatment Groups

THOMSON REUTERS
·
Jun 05

Amneal Announces Full Study Population Interim Phase 4 Elevate-Pd Results, Reinforcing Previously Reported Benefits of Crexont® in Parkinson's Disease

THOMSON REUTERS
·
Jun 05